The Study of Bisphosphonate Drug treatment in Periodontal and Periapical Disease

双膦酸盐类药物治疗牙周及根尖周疾病的研究

• 批准号: 11557146
• 负责人: TANI Nobuyuki
• 金额: $ 5.12万
• 依托单位: Kanagawa Dental College
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 1999
• 资助国家: 日本
• 起止时间: 1999 至 2000
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-11557146/
• 关键词: Bisphosphonates; Osteoclasts; Periodontitis; Periapical lesion; Incadronate; Bone resorption; YM175,; Bisphosphonate,; ラット根尖病変モデル、; ラット歯周炎モデル、; P.gingivalis; 骨吸収

Incadronate (YM175, disodium dihydrogen methylene-1,1-bisphosphonate), a bisphosphonate, was suggested to prevent the bone resorption associated with periodontitis by inhibition for the activity of osteoclast. The purpose of this study was to investigate the preventive effect of incadronate for periodontal destruction and periapical lesion. Periodontitis was induced to 35 Whister rats by inoculation of P. gingivalis to the oral cavity and by feeding a soft diet for 4 weeks. Incadronate was administered to oral cavity of the rats 2 days / week for 2, 4, and 8 weeks. Incadronate showed abilities to increase of the bone mineral density, and prevention of the bone loss by 8 weeks administration. These results showed that incadronate inhibits the bone resorption and the PMNs migration in periodontitis induced by P. gingivalis. Experimental periapical lesion was induced 20 Whister rats by the treatment of the pulp exposure to oral cavity for 2 or 4 weeks. Incadronate was administered to oral cavity of the rats 2 day/week for 2 and 4 weeks during experimental terms. Incadronate administration rats were increment of bone density and inflammatory cell migration in the periapical lesion on 4 weeks. Incadronate had abilities to increase the bone mineral density, and prevention the bone loss with 8 weeks administration. In conclusion, the results of these study showed that incadronate oral administration prevented alveolar bone loss in p. gingivalis infected rat periodontitis and periapical lesion. We conclude that incadronate may be a clinically drug treatment agent against alveolar bone in periodontitis.

建议双膦酸盐的墨酸盐（YM175，二氢二氢二氢二氢二氢），建议通过抑制破骨细胞活性，以防止与牙周炎相关的骨吸收。这项研究的目的是调查切入牙齿牙周破坏和根尖病变的预防作用。牙周炎通过接种牙龈疟原虫向口腔诱导了35只大鼠，并通过将软饮食喂养4周。将墨酸盐用于2天 /周的大鼠口腔2、4和8周。墨酸盐显示出增加骨矿物质密度的能力，并在8周给药时预防骨质流失。这些结果表明，胶菌在牙龈疟原虫诱导的牙周炎中抑制骨吸收和PMN迁移。通过将果肉暴露于口腔2或4周的情况下，诱导了20个鸟疱疹大鼠的实验性细胞性病变。在实验性的期间，将墨酸盐送给2天/周的大鼠口腔2和4周。入住大鼠的骨密度和炎症细胞迁移在4周内的骨密度和炎症细胞迁移。墨酸具有增加骨矿物质密度的能力，并通过8周的给药预防骨质流失。总之，这些研究的结果表明，摄取的口服给药阻止了p中的肺泡骨质流失。牙龈感染大鼠牙周炎和根尖病变。我们得出的结论是，在牙周炎中，墨酸可能是针对牙槽骨的临床药物治疗剂。